Journal
BRAIN RESEARCH
Volume 1593, Issue -, Pages 95-105Publisher
ELSEVIER
DOI: 10.1016/j.brainres.2014.09.068
Keywords
Parkinson's disease; Melatonin; Rotenone; Neuroprotective; Antidepressant
Categories
Funding
- CNPq [307735/2012-5]
- CAPES
- CNPq
- Fundacao Arauceria-Governo do Estado do Parana
Ask authors/readers for more resources
Parkinson's disease (PD) is a neurodegenerative disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). Systemic and intranigral exposure to rotenone in rodents reproduces many of the pathological and behavioral features of PD in humans and thus has been used as an animal model of the disease. Melatonin is a neurohormone secreted by the pineal gland, which has several important physiological functions. It has been reported to be neuroprotective in some animal models of PD. The present study investigated the effects of prolonged melatonin treatment in rats previously exposed to rotenone. The animals were intraperitoneally treated for 10 days with rotenone (2.5 mg/kg) or its vehicle. 24 h later, they were intraperitoneally treated with melatonin (10 mg/kg) or its vehicle for 28 days. One day after the last rotenone exposure, the animals exhibited hypolocomotion in the open field test, which spontaneously reversed at the last motor evaluation. We verified that prolonged melatonin treatment after dopaminergic lesion did not alter motor function but produced antidepressant-like effects in the forced swim test, prevented the rotenone-induced reduction of striatal dopamine, and partially prevented tyrosine hydroxylase immunoreactivity loss in the SNpc. Our results indicate that melatonin exerts neuroprotective and antidepressant-like effects in the rotenone model of PD. (C) 2014 Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available